In 2013, Scalici et al. suggested VCAM-1 as indicator for ovarian cancer response to platinum based chemotherapy [11], and in a recent study, correlated serum sVCAM- 1 with mesothelial VCAM-1 expression in 18 patients with ovarian cancer and were unable to identify serum sVCAM-1 as a surrogate for mesothelium expression [12]. Here, VCAM1 is linked to ovarian carcinoma.